Clinical Research Directory
Browse clinical research sites, groups, and studies.
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
Sponsor: Navy General Hospital, Beijing
Summary
The goal of this phase 2 trial is to test the safety and efficacy of zanubrutinib and lenalidomide as maintenance therapy in patients with DLBCL.
Official title: Zanubrutinib and Lenalidomide as Maintenance Therapy in Patients With Diffuse Large B-cell Lymphoma
Key Details
Gender
All
Age Range
14 Years - Any
Study Type
INTERVENTIONAL
Enrollment
240
Start Date
2024-08-30
Completion Date
2030-12-30
Last Updated
2024-09-19
Healthy Volunteers
No
Conditions
Interventions
Zanubrutinib plus Lenalidomide as Maintenance Therapy
Patients were treated by Zanubrutinib(160mg po bid d1-28) plus Lenalidomide(25mg po qd d1-14) as maintenance therapy until 2 years post chemotherpay
Locations (1)
Navy General Hospital
Beijing, Beijing Municipality, China